A Narrative Review on Various Treatment Methods for Coronary Microvascular Disease

Abstract

This investigation allowed us to understand more about the relationship between Plavix and the treatment of coronary microvascular dysfunction. The capacity of Plavix to work in tandem with aspirin in a dual treatment approach to improve the anti-platelet therapeutic impact and to lessen platelet aggregation brought on by platelet receptor blockade is one of the drug’s many important advantages. The researchers found that the average reduction in risk of adverse cardiovascular events caused by Plavix much outweighed any potential systemic harm. Although it has been shown that the current standard of care significantly lowers harm among people with micro cardiovascular disease, more study is needed to ensure that this standard is enhanced. It may become more typical in the future to include patient groups in trials without requiring diabetes as a requirement. It is possible that the study results are biased since diabetes patients often have higher LDL cholesterol levels than the overall population. To confirm or deny this claim, more investigation is necessary.